Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease

NCT02336646 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Limb Ischemia

Interventions

DRUG: Allogenic MSC
DRUG: Normal saline

Sponsor

Taiwan Bio Therapeutics Inc.